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Validity of an atopic dermatitis outcome measure for real-world clinical practice
Topham C; Haynes D; Brazil M; Simpson EL
Oregon Health & Science University, Department of Dermatology

Introduction: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the
United States. AD is associated with reduced quality of life and substantial financial costs, making it
burdensome at an individual and population level. Disease severity outcome measures are validated
tools to assess severity and therapeutic response. Recent consensus statements have identified goldstandard outcome measures for AD in clinical trials, but further work is needed evaluating outcome
measures feasible for clinical practice.
Objective: To investigate the validity and feasibility of the product of investigator global assessment and
body surface area (IGA x BSA) as an outcome measure for AD in the clinical setting.
Methods and Results: Retrospective chart review of patients with AD seen in an outpatient dermatology
clinic at Oregon Health & Science University from 2015-2018 with recorded BSA and IGA revealed 246
patients comprising 682 clinic visits. We observed strong and statistically significant correlations
between IGA x BSA and the gold-standard measurement for clinical signs in clinical trials, the Eczema
Area and Severity Index (r=0.9105, p <0.0001, n=19). IGA x BSA also showed strong correlations with the
average daily pruritus numerical rating scale (r=0.7108, p <0.0001, n=177) and the patient global
assessment (r=0.7389, p <0.0001, n=170).
Conclusions: IGA x BSA is a valid and feasible outcome measure for AD which aligns with patientreported disease severity and may be used in real-world clinical practice.

